---
created: 2025-04-13
updated: 2025-04-13T10:52
id: xK}FF?3)>R
specialty: derm
specialty_id: 83
tags:
  - source/ak-original-decks::step-1::zanki-step-decks::zanki-dermatology
  - source/ak-step1-v11::
  - theme/firstaid::02-immunology::04-immunosuppressants::03-recombinant-cytokines-&-clinical-uses::immunotherapy::imiquimod
  - source/ak-step1-v11::
  - theme/firstaid::11-musculoskeletal-skin-connective-tissue::03-derm::18-pharm
  - source/ak-step1-v11::
  - theme/firstaid::11-musculoskeletal-skin-connective-tissue::03-derm::18-pharm::imiquimod
  - source/ak-step1-v11::
  - source/ome-banner
  - source/ak-step1-v11::
  - theme/uworld::10000-99999::14000-14999::14488
  - source/ak-step1-v11::$ankingupdates::uworld
  - source/ak-step1-v11::^systems::dermatology::akadds"
type: flashcard
---

# Question
**Imiquimod** can be used to treat urogenital warts by activating **TLR-7**, leading to unregulated pro-inflammatory transcription factor **NF-kB** which initiates the immune response

---

# Answer
Extra: Imiquimod also inhibits angiogenesis and induces apoptosis by activating caspases